Prolacta's Human Milk-Based Nutrition Has Touched the Lives of 100,000 Premature and Critically Ill Infants Globally
Retrieved on:
Friday, November 17, 2023
Hospice and palliative medicine, Necrotizing enterocolitis, Disease, Premature, NICU, Pediatrics, Medical Center, BPD, Prenatal care, Neonatology, Mortality, ROP, Monica E. Peek, Place of birth, Retinopathy, Division, Health, Bronchopulmonary dysplasia, Exclusive, MD, Mother, Death, Extrapyramidal system, Hospital, Singing, NEC, Dietary supplement, Nursing, Birth control
DUARTE, Calif., Nov. 17, 2023 /PRNewswire/ -- Prolacta Bioscience, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, proudly commemorates Prematurity Awareness Month 2023 by announcing a significant milestone: more than 100,000 preterm and critically ill infants' lives have been touched by Prolacta's Exclusive Human Milk Diet (EHMD) in hospitals worldwide.1
Key Points:
- "We're proud that for more than two decades, Prolacta's 100% human milk-based nutritional products have supported hospitals on the forefront of progressive care to help so many fragile infants in need."
- The Peeks advocated for Leah Michelle to be on an EHMD and asked the hospital to fortify Brandi's breast milk with a Prolacta fortifier.
- All types of hospitals have seen the benefits of an EHMD to treat the critically ill, premature infants in their care, including those supporting underserved populations.
- One example is Los Angeles General Medical Center (formerly LAC+USC Medical Center), among the largest public hospitals in the U.S.